,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'destiny-breast03', 'breast']
reporting new data live from #asco22 more evidence of trastuzumab-deruxtecan s safety &amp; utility in her2+ metastatic bc! the destiny-breast03 safety follow-up finds this combination s safety profile to be both tolerable &amp; superior to trastuzumab-emtansine. 
Real time, on-demand personalized cancer education and support through our online educational platform